Abstract
Efalizumab is a recombinant humanized monoclonal antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T-cells that lead to the development of psoriasis. It has been approved in the US in 2003 and in Europe in 2004 for the treatment of adults with moderate to severe chronic plaque psoriasis for whom other systemic treatments or phototherapy have been inadequate or inappropriate. The currently suggested dose of 1mg/kg/wk has been shown to have significant therapeutic effect on psoriasis in several controlled trials. Efalizumab has a favorable safety and tolerability profile and provides dermatologists with a effective and safe treatment alternative. The solution to the conflict which is between the currently high cost of this drug and its suggested continuous use for long-term psoriasis control will dictate the future of efalizumab.
Keywords: Efalizumab, psoriasis, treatment, biologics
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Efalizumab
Volume: 6 Issue: 3
Author(s): Ekin Savk
Affiliation:
Keywords: Efalizumab, psoriasis, treatment, biologics
Abstract: Efalizumab is a recombinant humanized monoclonal antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T-cells that lead to the development of psoriasis. It has been approved in the US in 2003 and in Europe in 2004 for the treatment of adults with moderate to severe chronic plaque psoriasis for whom other systemic treatments or phototherapy have been inadequate or inappropriate. The currently suggested dose of 1mg/kg/wk has been shown to have significant therapeutic effect on psoriasis in several controlled trials. Efalizumab has a favorable safety and tolerability profile and provides dermatologists with a effective and safe treatment alternative. The solution to the conflict which is between the currently high cost of this drug and its suggested continuous use for long-term psoriasis control will dictate the future of efalizumab.
Export Options
About this article
Cite this article as:
Ekin Savk , Efalizumab, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (3) . https://dx.doi.org/10.2174/187152307781368292
DOI https://dx.doi.org/10.2174/187152307781368292 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Inflammation: A Review of Recent Advances in Anti- Inflammatory Strategies
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Bacterial Proteases in Disease – Role in Intracellular Survival, Evasion of Coagulation/ Fibrinolysis Innate Defenses, Toxicoses and Viral Infections
Current Pharmaceutical Design Hypertension: Quo Vadis?
Current Vascular Pharmacology Chips for Brains
Current Genomics Monocyte Cyclooxygenase-2 Activity: A New Therapeutic Target for Atherosclerosis?
Current Drug Targets - Cardiovascular & Hematological Disorders Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Current Drug Safety Alterations of the Kidney Cortex Proteome in Response to Exercise Training in Normoglycemic and Hyperglycemic Conditions
Current Topics in Medicinal Chemistry Incremental Value of Two Dimensional Speckle Tracking Echocardiography in the Functional Assessment and Characterization of Subclinical Left Ventricular Dysfunction
Current Cardiology Reviews Evaluating 3D-printed Bolus Compared to Conventional Bolus Types Used in External Beam Radiation Therapy
Current Medical Imaging Inflammatory Cardiovascular Risk Markers in Obstructive Sleep Apnoea Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Medicinal Chemistry of 2,2,4-Substituted Morpholines
Current Medicinal Chemistry Polypharmacology in a Single Drug: Multitarget Drugs
Current Medicinal Chemistry Fragment Pharmacophore-Based Screening: An Efficient Approach for Discovery of New Inhibitors of Toll-Like Receptor 5
Combinatorial Chemistry & High Throughput Screening Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews Antioxidants Suppress Th1-Type Immune Response In Vitro
Drug Metabolism Letters Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology The Physiology of Nitric Oxide: Control and Consequences
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Role of the Osteoprotegerin/RANKL/RANK System in Diabetic Vascular Disease
Current Medicinal Chemistry Big Science for Small Cells: Systems Approaches for Platelets
Current Drug Targets